ALFA Finder| Revenue growth | Flat YoY at ₹1,051cr; 9-month revenue up 3%. |
|---|---|
| Margins | EBITDA margin stable at 13%; Specialty segment sustained >25%. |
| Order book | Funnel expanded to 100+ opportunities with ₹3,500cr peak revenue potential. |
| Demand visibility | Strong recovery in agrochemical volumes; stable pharmaceutical demand. |
| Management confidence | Confident, focusing on new project execution and volume resilience. |
Growth
Revenue grew 3% for nine months with double-digit volume growth; EBITDA rose 8%.
Outlook
Projecting ₹500cr capex in FY27; CDMO order deliveries starting March 2026.
Risks
Subdued pricing in Specialty Chemicals and Vitamin B3; supply-demand imbalances in agrochemicals.
Earnings Call filed with NSE, NSE: JUBLINGREA. Summary written with AI assistance from the document.
Jubilant Ingrevia Ltd: key numbers
- Share price
- ₹607.00
- Market cap
- ₹9,668 Cr
- Revenue (annual)
- ₹4,388 Cr
- Net profit (annual)
- ₹277.9 Cr
- P/E (TTM)
- 27.6×Sector 35.5×
- Promoter holding
- 45.22%+0.00% QoQ
- FII holding
- 6.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Ingrevia Ltd
All →Jubilant Ingrevia Merger & Restructuring
Jubilant Ingrevia updated on a restructuring share subscription and purchase agreement closing in two tranches. First tranche is due by November 2026, second by September 2027.
- Execution
- First tranche by November 2026; second tranche by September 2027
Jubilant Ingrevia Acquisition
Jubilant Ingrevia's subsidiary JAEL signed the SSPA for a 40% stake in Zettaone, with an option to reach 51%. The deal enters electronics design and manufacturing services.
Jubilant Ingrevia Other Announcement
Jubilant Ingrevia Limited filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing records the holdings of promoters, public shareholders and other categories.
Jubilant Ingrevia Employee Stock Options
Jubilant Ingrevia Employees Welfare Trust bought 45,000 shares on NSE for ₹2.49 Crore under its ESOP scheme. Post-trade holding rose to 0.98% of total equity.
- Value
- ₹2.49 Cr
Jubilant Ingrevia Earnings Call Transcript: Key Takeaways
Strong Q2 performance driven by volume growth across specialty chemicals and nutrition despite price softness in China.
Jubilant Ingrevia Management Change
Jubilant Ingrevia's Sr. Vice President & Head HR, Ms. Vinita Koul, resigned effective November 6, 2026. The departure is to pursue other interests.